WO2015021041A3 - Systems, devices, and methods for alleviating glucotoxicity and restoring pancreatic beta-cell function in advanced diabetes mellitus - Google Patents

Systems, devices, and methods for alleviating glucotoxicity and restoring pancreatic beta-cell function in advanced diabetes mellitus Download PDF

Info

Publication number
WO2015021041A3
WO2015021041A3 PCT/US2014/049771 US2014049771W WO2015021041A3 WO 2015021041 A3 WO2015021041 A3 WO 2015021041A3 US 2014049771 W US2014049771 W US 2014049771W WO 2015021041 A3 WO2015021041 A3 WO 2015021041A3
Authority
WO
WIPO (PCT)
Prior art keywords
patient
systems
methods
devices
diabetes mellitus
Prior art date
Application number
PCT/US2014/049771
Other languages
French (fr)
Other versions
WO2015021041A2 (en
Inventor
Eran Bashan
Israel Hodish
Original Assignee
Hygieia, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hygieia, Inc. filed Critical Hygieia, Inc.
Priority to EP14833783.5A priority Critical patent/EP3030140B1/en
Priority to CN201480054905.5A priority patent/CN105592779A/en
Priority to BR112016002598-9A priority patent/BR112016002598B1/en
Publication of WO2015021041A2 publication Critical patent/WO2015021041A2/en
Publication of WO2015021041A3 publication Critical patent/WO2015021041A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
    • A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4842—Monitoring progression or stage of a disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M2005/14288—Infusion or injection simulation
    • A61M2005/14292—Computer-based infusion planning or simulation of spatio-temporal infusate distribution

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Primary Health Care (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Emergency Medicine (AREA)
  • Artificial Intelligence (AREA)
  • Signal Processing (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Systems, methods and/or devices for treating diabetes mellitus by alleviating glucotoxicity and restoring pancreatic beta-cell function, comprising at least a first memory for storing data inputs corresponding at least to one or more components in a patient's present insulin dosage regimen, and data inputs corresponding at least to the patient's blood-glucose-level measurements determined at a plurality of times, and a processor operatively connected to the at least first memory. The processor determines from the data inputs whether and by how much to vary at least one of the components of the patient's present insulin dosage regimen. Also disclosed is establishing the patient's current glycemic state relative to a desired glycemic range and determining from at least one of a plurality of the data corresponding to the patient's blood glucose-level measurements whether and by how much to adjust at least one of the components in the patient's present insulin dosage regimen.
PCT/US2014/049771 2013-08-05 2014-08-05 Systems, devices, and methods for alleviating glucotoxicity and restoring pancreatic beta-cell function in advanced diabetes mellitus WO2015021041A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP14833783.5A EP3030140B1 (en) 2013-08-05 2014-08-05 Systems and devices for alleviating glucotoxicity and restoring pancreatic beta-cell function in advanced diabetes mellitus
CN201480054905.5A CN105592779A (en) 2013-08-05 2014-08-05 Systems, devices, and methods for alleviating glucotoxicity and restoring pancreatic beta-cell function in advanced diabetes mellitus
BR112016002598-9A BR112016002598B1 (en) 2013-08-05 2014-08-05 Device and system to alleviate glucotoxicity and/or restore pancreatic beta cell function in a patient

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361862327P 2013-08-05 2013-08-05
US61/862,327 2013-08-05

Publications (2)

Publication Number Publication Date
WO2015021041A2 WO2015021041A2 (en) 2015-02-12
WO2015021041A3 true WO2015021041A3 (en) 2015-04-09

Family

ID=52462031

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/049771 WO2015021041A2 (en) 2013-08-05 2014-08-05 Systems, devices, and methods for alleviating glucotoxicity and restoring pancreatic beta-cell function in advanced diabetes mellitus

Country Status (4)

Country Link
EP (1) EP3030140B1 (en)
CN (2) CN105592779A (en)
BR (1) BR112016002598B1 (en)
WO (1) WO2015021041A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018525093A (en) 2015-08-07 2018-09-06 トラスティーズ オブ ボストン ユニバーシティ Glucose control system with automatic adaptation of glucose targets
EP3481274B1 (en) * 2016-07-08 2023-01-25 Novo Nordisk A/S Basal titration with adaptive target glucose level
EP4000075A4 (en) 2019-07-16 2023-10-04 Beta Bionics, Inc. Blood glucose control system
EP3998943A4 (en) 2019-07-16 2023-09-06 Beta Bionics, Inc. Blood glucose control system
US11957876B2 (en) 2019-07-16 2024-04-16 Beta Bionics, Inc. Glucose control system with automated backup therapy protocol generation
US11594314B2 (en) 2020-12-07 2023-02-28 Beta Bionics, Inc. Modular blood glucose control systems

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120022353A1 (en) * 2008-04-04 2012-01-26 Hygieia, Inc. System for Optimizing a Patient's Insulin Dosage Regimen
US20130165901A1 (en) * 2011-12-21 2013-06-27 EndoTool, LLC Systems and methods for determining insulin therapy for a patient

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) * 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
WO2005113036A1 (en) * 2004-05-13 2005-12-01 The Regents Of The University Of California Method and apparatus for glucose control and insulin dosing for diabetics
US20070078314A1 (en) * 2005-09-30 2007-04-05 Grounsell Richard L System and method for measuring and predicting insulin dosing rates
ES2576639T3 (en) * 2007-06-20 2016-07-08 F.Hoffmann-La Roche Ag Method and device to assess the ratio of carbohydrates to insulin
US9220456B2 (en) * 2008-04-04 2015-12-29 Hygieia, Inc. Systems, methods and devices for achieving glycemic balance
US9918635B2 (en) * 2008-12-23 2018-03-20 Roche Diabetes Care, Inc. Systems and methods for optimizing insulin dosage
KR20110097889A (en) * 2008-12-23 2011-08-31 에프. 호프만-라 로슈 아게 Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device
WO2010097796A1 (en) * 2009-02-26 2010-09-02 Mor Research Applications Ltd. Method and system for automatic monitoring of diabetes related treatments
WO2011041007A1 (en) * 2009-09-29 2011-04-07 Lifescan Scotland Limited Analyte testing method and device for diabetes management
WO2011039741A1 (en) * 2009-09-30 2011-04-07 Mor Research Applications Ltd. Monitoring device for mangement of insulin delivery

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120022353A1 (en) * 2008-04-04 2012-01-26 Hygieia, Inc. System for Optimizing a Patient's Insulin Dosage Regimen
US20130165901A1 (en) * 2011-12-21 2013-06-27 EndoTool, LLC Systems and methods for determining insulin therapy for a patient

Also Published As

Publication number Publication date
BR112016002598A2 (en) 2017-08-01
EP3030140A2 (en) 2016-06-15
CN113940627A (en) 2022-01-18
EP3030140B1 (en) 2019-06-19
WO2015021041A2 (en) 2015-02-12
CN105592779A (en) 2016-05-18
BR112016002598B1 (en) 2022-06-21
EP3030140A4 (en) 2017-02-08

Similar Documents

Publication Publication Date Title
WO2015021041A3 (en) Systems, devices, and methods for alleviating glucotoxicity and restoring pancreatic beta-cell function in advanced diabetes mellitus
World Health Organization Global report on diabetes: executive summary
WO2014100715A3 (en) Supplements and monitoring systems for dosing of the supplements
WO2013037754A3 (en) Adaptive system for optimizing a drug dosage regimen over time
EP4079383A3 (en) Method and system for interacting with a virtual environment
WO2014179594A3 (en) System and method for monitoring administration of nutrition
WO2012040248A3 (en) Automatic association of medical elements
MX2019003646A (en) System and method for performing alternative and sequential blood and peritoneal dialysis modalities.
WO2012145752A3 (en) Wearable automatic injection device
MX2020010004A (en) Therapeutic uses of empagliflozin.
WO2014100736A3 (en) Computer-implemented method, system, and apparatus for electronic patient care
WO2013032705A3 (en) Determining an effective stress level on a processor
WO2014149964A8 (en) Systems and methods for use in diagnosing a medical condition of a patient
WO2013109342A8 (en) Method of treating diabetes using non-glycosylated apolipoprotein a-iv
WO2015003122A3 (en) Regulation of glucose metabolism using anti-cgrp antibodies
TN2016000083A1 (en) Methods and tools relating to the administration of contrast medium
MX2016005064A (en) Immersion device.
WO2014184666A3 (en) Cell therapy for myelodysplastic syndromes
Gracia et al. WJD 5~(th) Anniversary Special Issues (2): Type 2 diabetes Structured SMBG in early management of T2DM: Contributions from the St Carlos study
Gjedsted Severe hypoglycemia: case report
张盼 Association of anxiety and hemoglobin A_1c in patients with type 2 diabetes mellitus
Li China Medical Board Open Competition Interview Series: Part II
Dixit Alcohol/disulfiram interaction
WO2013140423A8 (en) Method for controlling the delivery of insulin and the related system
Ashcheulova et al. Distant apoptosis markers-FasL (CD95L) and FasR (CD95, APO-1) at hypertensive patients with prediabetes and type 2 diabetes mellitus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14833783

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016002598

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2014833783

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 112016002598

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160204